X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BT051 is an oral, locally-acting inhibitor of neutrophil trafficking and activation and is in clinical development for the treatment of inflammatory bowel disease (IBD), which impacts as many as 6.8 million people in the United States and Europe.
Lead Product(s): BT051
Therapeutic Area: Gastroenterology Product Name: BT051
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2021
Details:
Single doses of BT051 up to 3500 mg were generally safe and well tolerated in all healthy subjects exposed. Bacainn Therapeutics plans to initiate a Phase 1b clinical trial of BT051 in patients with moderate to severe active ulcerative colitis, based on the study results.
Lead Product(s): BT051
Therapeutic Area: Gastroenterology Product Name: BT051
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
The Phase 1 clinical trial is evaluating various dose levels of BT051 for safety, tolerability and pharmacokinetics in a double-blind, placebo-controlled study in healthy volunteers.
Lead Product(s): BT051
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
